CeriBell (NASDAQ:CBLL) Given Average Recommendation of "Buy" by Analysts

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) have received an average rating of "Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $32.60.

Several analysts have recently issued reports on the stock. TD Cowen lifted their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Canaccord Genuity Group lifted their price objective on CeriBell from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Monday, December 9th. JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They set an "overweight" rating and a $32.00 target price for the company. William Blair began coverage on CeriBell in a research report on Tuesday, November 5th. They issued an "outperform" rating on the stock. Finally, Bank of America started coverage on CeriBell in a research report on Tuesday, November 5th. They set a "buy" rating and a $32.00 price target for the company.

CeriBell Stock Up 1.0 %

NASDAQ CBLL traded up $0.26 during trading hours on Wednesday, reaching $26.98. The company's stock had a trading volume of 107,356 shares, compared to its average volume of 249,611. CeriBell has a 1-year low of $23.00 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. Analysts predict that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.